Dexcel Pharma is Israel’s largest private pharmaceutical
company. Founded in 1968, we develop, manufacture
and market value-added branded and generic
pharmaceuticals. With a diverse product portfolio that
spans more than 55 branded and generic products in
over 140 dosage forms, our products are sold in the US,
the UK and Germany, via subsidiaries and through a
trusted network of partners in more than 30 countries worldwide.
Track Record of Market innovation and Success
History of successful development and commercialization of novel drug formulations utilizing Dexcel’s proprietary drug delivery technologies. Dexcel’s Omeprazole Delayed-Release Tablet – a Proton Pump Inhibitor – is the bestselling Over-The-Counter product in the US heartburn market category.
Dexcel’s R&D approach applies creative thinking across multiple dimensions to bring innovation to address patient unmet needs. Dexcel’s philosophy calls for imagination in drug formulation, sophisticated regulatory strategy, and careful product selection.
Fully automated manufacturing facilities for oral solid dose forms are located in the central Israel city of Or Akiva, alongside corporate headquarters and R&D. Additional research and manufacturing facilities are located in Yokneam and Jerusalem.